Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of Compensation Expense and Related Income Tax Benefit

The compensation expense from the Company’s share-based compensation plans and associated income tax benefit, excluding the effects of excess tax benefits or shortfalls, were included in the Consolidated Statements of Operations as follows (in millions):

	Year Ended December 31,
Compensation costs and related income tax benefit	2022		2021		2020
Cost of sales	$	6	$	8	$	6
Selling and marketing	22		26		16
Research and development	34		28		16
General and administration	34		31		21
Total compensation expense	$	96	$	93	$	59
Income tax benefit	$	17	$	14	$	9

Summary of Equity Awards Activity

A summary of the Company’s restricted and performance stock-settled awards for the years ended December 31, 2022, 2021 and 2020 is as follows:

	Year Ended December 31, 2022
	RSUs			PSUs			RSAs			PSAs
	Units	Weighted-Average Grant Date Fair Value		Units	Weighted-Average Grant Date Fair Value		Shares	Weighted-Average Grant Date Fair Value		Shares	Weighted-Average Grant Date Fair Value
Outstanding at beginning of year	130,009	$	518.80	37,691	$	482.42	154,322	$	253.54	74,032	$	225.34
Granted	181,351	359.02		70,777	367.16		6,122	321.03		—	—
Released	(48,095)	518.64		(226)	482.42		(104,891)	248.36		(38,671)	206.62
Forfeited	(20,533)	463.11		(2,314)	410.80		(8,582)	259.93		(115)	244.62
Outstanding at end of year	242,732	$	404.19	105,928	$	406.89	46,971	$	271.92	35,246	$	245.79

	Year Ended December 31, 2021
	RSUs			PSUs			RSAs			PSAs
	Units	Weighted-Average Grant Date Fair Value		Units	Weighted-Average Grant Date Fair Value		Shares	Weighted-Average Grant Date Fair Value		Shares	Weighted-Average Grant Date Fair Value
Outstanding at beginning of year	—	$	—	—	$	—	318,565	$	228.08	126,022	$	199.77
Granted	134,419	518.39		38,393	482.42		6,005	486.02		—	—
Released	(674)	489.16		—	—		(159,702)	212.33		(49,236)	160.11
Forfeited	(3,736)	509.58		(702)	482.42		(10,546)	239.78		(2,754)	236.18
Outstanding at end of year	130,009	$	518.80	37,691	$	482.42	154,322	$	253.54	74,032	$	225.34

	Year Ended December 31, 2020
	RSAs			PSAs
	Shares	Weighted-Average Grant Date Fair Value		Shares	Weighted-Average Grant Date Fair Value
Outstanding at beginning of year	434,641	$	151.52	170,749	$	144.47
Granted	178,150	265.06		98,820	239.79
Released	(275,318)	133.43		(131,943)	160.18
Forfeited	(18,908)	199.04		(11,604)	194.23
Outstanding at end of year	318,565	$	228.08	126,022	$	199.77

Summary of SARs Activity

A summary of the Company’s SARs is as follows:

	2022			2021			2020
SARs	SARs	Weighted-Average Grant Date Exercise Price		SARs	Weighted-Average Grant Date Exercise Price		SARs	Weighted-Average Grant Date Exercise Price
Outstanding at beginning of year	474,151	$	121.05	638,124	$	113.98	896,923	$	89.05
Granted	—	—		—	—		69,742	253.62
Exercised	(28,659)	88.35		(159,035)	89.87		(295,770)	67.96
Forfeited	(1,987)	229.46		(4,938)	213.80		(31,193)	149.09
Expired	(29)	205.12		—	—		(1,578)	166.52
Outstanding at end of year	443,476	$	122.67	474,151	$	121.05	638,124	$	113.98
Exercisable at end of year	400,351	$	110.14	383,273	$	97.29	417,856	$	81.88

Summary of Information for SARs Outstanding

The following table summarizes information about SARs outstanding as of December 31, 2022:

	Outstanding		Exercisable
Aggregate intrinsic value (in millions)	$	60	$	59
Weighted-average remaining contractual life (in years)	2.6		2.5